Neuroendocrinology News

Somatostatin receptors may have utility as diagnostic, prognostic and therapeutic markers of bronchopulmonary neuroendocrine neoplasms, according to research published in The Journal of Clinical Endocrinology & Metabolism.

Combination treatment with temsirolimus and bevacizumab demonstrated considerable activity and a reasonable safety profile in patients with progressive pancreatic neuroendocrine tumors, according to results of a phase 2 trial.

A somatic mutation in the ATP-dependent helicase, or ATRX,  gene — recently demonstrating potential as a molecular marker for aggressive brain tumors — could also serve as a biomarker for rare neuroendocrine tumors, according to research published in Nature Communications.

The 12-month results from an extension study looking at long-term safety and efficacy of a novel, long-acting form of recombinant human growth hormone (rhGH) developed by Versartis Inc. are encouraging, according to a press release.

The FDA today approved lanreotide for treatment of patients with unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.

The FDA has approved a long-acting release formulation of pasireotide to treat patients with acromegaly who have either not responded to surgery or for whom surgery is not an option, according to statement from the drug developer.

With infusion of tumor necrosis factor-alpha, healthy men had greater increases in urea and amino acid fluxes and endogenous glucose production than men with hypopituitarism, according to research published in The Journal of Clinical Endocrinology & Metabolism.

Hybrid neuroimaging of the pituitary region of the brain could help distinguish military veterans with posttraumatic stress disorder from those with mild traumatic brain injury, according to research presented at the annual meeting of the Radiological Society of North America.

Gleason scores among patients with conventional prostatic adenocarcinoma was significantly associated with time to development of treatment-related neuroendocrine prostate cancer, according to study results.

A new clinical practice guideline developed by The Endocrine Society and published the Journal of Clinical Endocrinology & Metabolism addresses evaluation and management of acromegaly.